Dr. Sumanta K. Pal: CD70-Targeted Allogeneic CAR T-Cell Therapy for ccRCC
Read the paper: https://doi.org/10.1158/2159-8290.CD-24-0102
Read the paper: https://doi.org/10.1158/2159-8290.CD-24-0102
AbstractPancreatic ductal adenocarcinoma (PDAC) therapeutic resistance is largely attributed to a unique tumor microenvironment embedded with an abundance of cancer-associated fibroblasts (CAF). Distinct CAF populations…
Raajit K. Rampal, MD, PhD, discusses choosing among JAK inhibitors based on specific patient needs, such as platelet counts and anemia, emphasizing the importance of…
AbstractThe tumor microenvironment (TME) profoundly influences tumorigenesis, with gene expression in the breast TME capable of predicting clinical outcomes. The TME is complex and includes…
Knowing what symptoms to look for can help your doctor find cancer early when it’s most treatable.
Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while…
Matthew Lunning, DO, FACP, discusses the use of CAR T-cell therapy lisocabtagene maraleucel in the second-line setting for patients with B-cell lymphoma.
Abstract. Serine metabolism plays a pivotal role in cancer, making it an appealing therapeutic target. Two recent studies published in Nature Metabolism and Science Translational…
Abstract. Gain-of-function mutations in the histone acetylation ‘reader’ ENL, found in AML and Wilms tumor, are known to drive condensate formation and gene activation in…
Domenica Lorusso, MD, PhD, presents the final overall survival data from the randomized open -label phase 2 trial of relacorilant, a selective glucocorticoid receptor modulator…
An abstract is unavailable.